我院2015～2017年抗肿瘤口服中成药的用药情况
|
摘要
目的探讨我院2015~2017年抗肿瘤口服中成药的用药情况。方法选择Microsoft Excel软件分析和统计我院2015~2017年抗肿瘤口服中成药的金额、品种、药品费用占比、日均费用(DDC)、用药频度(DDDs)等。结果 2015年度抗肿瘤口服中成药金额所占药品总金额的比例为1.45%,2016年度的占比为1.24%,2017年度的占比为1.17%。单品种用药金额排前4位的分别为艾愈胶囊、地榆升白片、维血宁颗粒、康莱特胶囊。DDDs前4位的抗肿瘤口服中成药分别为艾愈胶囊、地榆升白片、维血宁颗粒、康莱特胶囊。药品DDC前4位的抗肿瘤口服中成药分别为艾愈胶囊、地榆升白片、维血宁颗粒、康莱特胶囊。结论我院抗肿瘤口服中成药的用药情况基本合理,金额表现为逐年上升,在实际的临床用药中应加强管理和监督,进而对用药风险进行有效规避。
Objective To investigate the medication situation of antitumor oral Chinese patent medicines in our hospital from 2015 to 2017.Methods Microsoft Excel software was selected to analyze and count the amount,type,percentage of drug costs,daily average cost(DDC),and frequency of drug use(DDDs) of anticancer oral Chinese patent medicines from2015 to 2017 in our hospital.Results In 2015,the proportion of the total amount of anti-tumor Chinese patent medicines accounted for 1.45% of the total amount of drugs,the proportion in 2016 was 1.24%,and the proportion in 2017 was1.17%.The top four in terms of the amount of drugs used for a single variety were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Granules and Kanglaite Capsules.The top four antitumor oral Chinese medicines of DDDs were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Capsules and Kanglaite Capsules,and the top four antitumor oral Chinese medicines for the DDC of drugs were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Capsules and Kanglaite Capsules.Conclusion The use of antitumor oral Chinese patent medicine in our hospital is basically reasonable,the amount of performance is increasing year by year,in the actual clinical use of drugs should strengthen management and supervision,and then to effectively evade the risk of medication.
Objective To investigate the medication situation of antitumor oral Chinese patent medicines in our hospital from 2015 to 2017.Methods Microsoft Excel software was selected to analyze and count the amount,type,percentage of drug costs,daily average cost(DDC),and frequency of drug use(DDDs) of anticancer oral Chinese patent medicines from2015 to 2017 in our hospital.Results In 2015,the proportion of the total amount of anti-tumor Chinese patent medicines accounted for 1.45% of the total amount of drugs,the proportion in 2016 was 1.24%,and the proportion in 2017 was1.17%.The top four in terms of the amount of drugs used for a single variety were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Granules and Kanglaite Capsules.The top four antitumor oral Chinese medicines of DDDs were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Capsules and Kanglaite Capsules,and the top four antitumor oral Chinese medicines for the DDC of drugs were Aiyu Capsules,Diyu Shengbai Tablets,Weixuening Capsules and Kanglaite Capsules.Conclusion The use of antitumor oral Chinese patent medicine in our hospital is basically reasonable,the amount of performance is increasing year by year,in the actual clinical use of drugs should strengthen management and supervision,and then to effectively evade the risk of medication.
引文
[1]刘明.2014~2015年抗肿瘤中成药用药情况调查分析[J].检验医学与临床,2018,15(2):234-236.
[2]苏玉贞,孙丽,王媛,等.2016年天津市肿瘤医院门诊口服抗肿瘤中成药的不合理处方分析[J].现代药物与临床,2017,32(9):1785-1790.
[3]钱先中,王冬雪,仵利军,等.中成药制剂抗肿瘤作用的应用分析[J].中医药导报,2017,23(7):61-63,66.
[4]陈勇,杨燕,陈霞,等.临床合理应用抗肿瘤中成药的评估及干预措施分析[J].河北医学,2017,23(3):495-498.
[5]袁芳,吴秀芝.某医院2013~2015年对肿瘤患者应用中成药的合理性分析[J].解放军预防医学杂志,2017,35(1):44-46.
[6]彭云云,胡燕.2013~2015年我院抗肿瘤药物及其辅助药物应用分析[J].中国医药导报,2017,14(2):118-121.
[7]陈国梅,杨忠慧,成昌娟.某院肿瘤科抗肿瘤中成药临床药师干预前后对比分析[J].临床合理用药杂志,2017,10(1):43-44,47.
[8]徐凯,郭勇.抗肿瘤中成药应用概况调查及探讨[J].浙江中西医结合杂志,2011,21(10):735-736.
[9]陈果,王雄彪.常用抗肿瘤中成药治疗肺癌临床研究进展[J].辽宁中医药大学学报,2012,14(3):63-67.
[10]孙家艳,茅渊,朱静.我院近两年抗肿瘤中成药及辅助用药的应用分析[J].现代中药研究与实践,2016,30(2):79-82,86.
[11]刘必铿.我院2013年门诊抗肿瘤中成药用药分析[J].光明中医,2015,30(10):2238-2241.
[12]徐艳,相延英.2011~2013年医院抗肿瘤中成药应用分析[J].湖北中医杂志,2015,37(8):62-63.
[13]王媛媛,贾立群.中成药在肿瘤临床上的合理应用[J].中国乡村医药,2014,21(13):75-77.
[14]简晓顺,陈健清.近三年来我院抗肿瘤中成药用药分析[J].现代医院,2013,13(4):67-68.
[15]童本定,丁年羊,魏青.我院2009~2011年抗肿瘤药应用分析[J].中国药房,2012,23(42):3960-3963.
[2]苏玉贞,孙丽,王媛,等.2016年天津市肿瘤医院门诊口服抗肿瘤中成药的不合理处方分析[J].现代药物与临床,2017,32(9):1785-1790.
[3]钱先中,王冬雪,仵利军,等.中成药制剂抗肿瘤作用的应用分析[J].中医药导报,2017,23(7):61-63,66.
[4]陈勇,杨燕,陈霞,等.临床合理应用抗肿瘤中成药的评估及干预措施分析[J].河北医学,2017,23(3):495-498.
[5]袁芳,吴秀芝.某医院2013~2015年对肿瘤患者应用中成药的合理性分析[J].解放军预防医学杂志,2017,35(1):44-46.
[6]彭云云,胡燕.2013~2015年我院抗肿瘤药物及其辅助药物应用分析[J].中国医药导报,2017,14(2):118-121.
[7]陈国梅,杨忠慧,成昌娟.某院肿瘤科抗肿瘤中成药临床药师干预前后对比分析[J].临床合理用药杂志,2017,10(1):43-44,47.
[8]徐凯,郭勇.抗肿瘤中成药应用概况调查及探讨[J].浙江中西医结合杂志,2011,21(10):735-736.
[9]陈果,王雄彪.常用抗肿瘤中成药治疗肺癌临床研究进展[J].辽宁中医药大学学报,2012,14(3):63-67.
[10]孙家艳,茅渊,朱静.我院近两年抗肿瘤中成药及辅助用药的应用分析[J].现代中药研究与实践,2016,30(2):79-82,86.
[11]刘必铿.我院2013年门诊抗肿瘤中成药用药分析[J].光明中医,2015,30(10):2238-2241.
[12]徐艳,相延英.2011~2013年医院抗肿瘤中成药应用分析[J].湖北中医杂志,2015,37(8):62-63.
[13]王媛媛,贾立群.中成药在肿瘤临床上的合理应用[J].中国乡村医药,2014,21(13):75-77.
[14]简晓顺,陈健清.近三年来我院抗肿瘤中成药用药分析[J].现代医院,2013,13(4):67-68.
[15]童本定,丁年羊,魏青.我院2009~2011年抗肿瘤药应用分析[J].中国药房,2012,23(42):3960-3963.